Human Immunology News Volume 8.39 | Oct 6 2020

    0
    63







    HIN 8.39 | Oct 6 2020


    Human Immunology News by STEMCELL Technologies
    Vol. 8.39 – 6 October, 2020
    TOP STORY

    Disturbed Mitochondrial Dynamics in CD8+ TILs Reinforce T Cell Exhaustion

    Researchers found that T lymphocytes accumulated depolarized mitochondria as a result of decreased mitophagy activity and displayed functional, transcriptomic and epigenetic characteristics of terminally exhausted T cells.
    [Nature Immunology]

    Abstract

    The StemSpanâ„¢ T Cell Generation Kit is designed to promote differentiation of HSPCs into T cells in stroma- and serum-free culture conditions.
    PUBLICATIONSRanked by the impact factor of the journal

    Bispecific
    Anti-CD20, Anti-CD19 CAR T Cells for Relapsed B Cell Malignancies: A Phase I Dose Escalation and Expansion Trial

    Investigators conducted a first-in-human trial of bispecific anti-CD20, anti-CD19 CAR T cells for relapsed, refractory B cell malignancies.
    [Nature Medicine]

    Abstract

    Structural
    Basis for Substrate Recognition and Chemical Inhibition of Oncogenic MAGE Ubiquitin Ligases

    Researchers report the structural basis for substrate recognition by melanoma antigen (MAGE) ubiquitin ligases. Biochemical analysis of the degron motif recognized by MAGE-A11 and the crystal structure of MAGE-A11 bound to the PCF11 substrate uncovered a conserved substrate binding cleft in MAGEs.
    [Nature Communications]

    Full Article

    STAT5
    Promotes Accessibility and Is Required for BATF-Mediated Plasticity at the Il9 Locus

    Scientists showed that STAT5 was the earliest factor binding and remodeling the Il9 locus to allow BATF binding in both mouse and human Th9 cultures.
    [Nature Communications]

    Full Article

    Immunological
    Fingerprint of 4CMenB Recombinant Antigens via Protein Microarray Reveals Key Immunosignatures Correlating with Bactericidal Activity

    The authors describe the development and use of an ad hoc protein microarray to study the immune response induced by the three major 4CMenB antigenic components in individual sera from vaccinated infants, adolescents and adults.
    [Nature Communications]

    Full Article

    The
    Transcription Factor C/EBPβ Orchestrates Dendritic Cell Maturation and Functionality Under Homeostatic and Malignant Conditions

    Researchers identified the transcription factor C/EBPβ as a key regulator for dendritic cell maturation and immunogenic functionality under homeostatic and lymphoma-transformed conditions.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    The
    Purinergic Receptor P2Y11 Choreographs the Polarization, Mitochondrial Metabolism, and Migration of T Lymphocytes

    Scientists found that autocrine stimulation of the purinergic receptor P2Y11 regulated the migration of human CD4 T cells. P2Y11 receptors redistributed from the front to the back of polarized cells where they triggered intracellular cAMP/PKA signals that attenuated mitochondrial metabolism at the back.
    [Science Signaling]

    Abstract

    T
    Cell Repertoire Analysis Suggest a Prominent Bystander Response in Human Cardiac Allograft Vasculopathy

    Researchers used T-cell receptor β chain (sequencing to study the T-cell repertoire in the coronary artery, endomyocardium, and peripheral blood at the time of retransplant in four cases of cardiac allograft vasculopathy and compared it to the immunoglobulin heavy chain repertoire from the same samples.
    [American Journal of Transplantation]

    Abstract

    BAFF-Driven NLRP3 Inflammasome Activation in B Cell

    The authors report BAFF engagement to BAFF receptor elicited both priming and activating signals for NLRP3 inflammasomes in primary B cells and B lymphoma cell lines.
    [Cell Death & Disease]

    Full Article

    The
    Immune Receptor CD300e Negatively Regulates T Cell Activation by Impairing the STAT1-Dependent Antigen Presentation

    Investigators demonstrated that the ligation of CD300e in monocytes hampered the expression of the human leukocyte antigen class II, affecting its synthesis.
    [Scientific Reports]

    Full Article

    How can evaluating the immuno-oncology potential of compounds in vitro predict clinical outcomes? Watch this webinar by Dr. Alison O'Mahony, Eurofins DiscoverX
    REVIEWS

    Sex Steroids and Autoimmune Rheumatic Diseases: State of the Art

    Future clinical research needs to focus on the therapeutic use of androgens and progestins or their downstream signaling cascades and on new oestrogenic compounds such as tissue-selective oestrogen complex to modulate altered immune responses.
    [Nature Reviews Rheumatology]

    Abstract

    Transcription
    Tipping Points for T Follicular Helper Cell and T-Helper 1 Cell Fate Commitment

    The authors review the current information on the mode of action of the lineage-defining transcription factors Bcl6 and T-bet and how they act individually and in complex to govern CD4+ T-cell ontogeny.
    [Cellular & Molecular Immunology]

    Full Article

    Cell Death in the Tumor Microenvironment: Implications for Cancer Immunotherapy

    Investigators summarize evidence that apoptosis and efferocytosis are exploited in cancer, as well as discuss current translation and clinical efforts to harness signals from dying cells into therapeutic strategies.
    [Cells]

    Full Article

    INDUSTRY AND POLICY NEWS

    Oncocyte
    Agrees to Enter Licensing and Collaboration Agreement with Chronix Biomedical

    Oncocyte Corporation announced that it has agreed to enter a licensing and collaboration agreement with Chronix Biomedical. Oncocyte is licensing Chronix’s patented CNI Monitor technology for the TheraSure™-CNI MONITOR clinical assay.
    [Oncocyte Corporation]

    Press Release

    Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies

    Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced that their investigational new drug application for TNB-486, a bispecific T-cell engaging antibody for the treatment of B-Cell Non-Hodgkin’s lymphoma was cleared for the initiation of Phase I clinical studies by the FDA on September 30, 2020.
    [Teneobio, Inc.]

    Press Release

    FEATURED EVENT

    CAR-T Beyond Oncology Digital Event

    November 18, 2020
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral
    Associate – Immune Modulatory Therapies

    Houston Methodist Research Institute – Houston, Texas, United States

    Research
    Positions – Cancer and Immunotherapy

    Terasaki Research Institute – Los Angeles, California, United States

    Postdoctoral Researcher – Immune Oncology

    Princess Margaret Cancer Center – Toronto, Ontario, Canada

    Scientist Position – Skin Immunology

    University of California, Davis – Sacramento, California, United States


    Postdoctoral Fellowship – Innate Immunity and DNA Repair

    Stockholm University – Stockholm, Sweden

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Human Immunology News
    Archives Contact Us
    Human Immunology News Twitter